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Abstract The recently solved X-ray structure of the extracel-
lular portion of the interleukin-6 (IL-6) receptor (IL-6R) re-
vealed an IL-6R dimer in the crystal lattice which probably
represents a physiological dimer. Performing coprecipitation ex-
periments with two di¡erently tagged IL-6R variants expressed
in COS-7 cells, we show that an IL-6R dimer exists in the
plasma membrane in the absence of IL-6. Ligand binding does
not seem to a¡ect the dimerization status. When lysates of
COS-7 cells expressing only one of the IL-6R variants are
mixed, spontaneous dimerization occurs. Thus, the IL-6R dimer
observed in the crystal structure represents a physiologically
occurring phenomenon.
, 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Interleukin-6 (IL-6) activates cells by binding to the speci¢c
IL-6 receptor K-chain followed by recruitment of two signal-
transducing gp130 molecules, the L-receptors. Homodimeriza-
tion of gp130 triggers activation of intracellular signalling
cascades including the JAK/STAT- and ras/MAP-kinase path-
ways [1], whereas the IL-6 receptor (IL-6R) is not involved in
signal transduction as exempli¢ed by a biologically active
soluble IL-6R [2]. In di¡erence to IL-6, a viral interleukin-6
homolog, vIL-6, can directly induce a gp130 homodimer with-
out requirement for the IL-6RK [3]. The exact stoichiometry
of the IL-6 receptor (IL-6R) complex is controversial and may
consist of a tetramer of IL-6, IL-6RK, and gp130 in a 1:1:2
stoichiometry or a hexamer in a 2:2:2 stoichiometry or both
[4,5]. Receptors of the IL-6 family are type I cytokine recep-
tors that are characterized by a cytokine binding module
(CBM) constituted by two ¢bronectin type III-like domains
of 100 amino acid length in roughly perpendicular orientation
to each other [6], a con¢guration con¢rmed by the solved
X-ray structure of the CBM of gp130 [7]. The NH2-terminal
domain contains four conserved cysteine residues, the COOH-
terminal one a conserved WSXWS motif that is part of a
structurally relevant ‘tryptophane-zipper’ motif [8]. In the
viral IL-6/gp130 complex, the CBM of gp130 contacts the
site II receptor binding epitope of vIL-6, whereas an addi-
tional Ig-like domain at the NH2-terminus of the gp130
CBM is required to contact the site III epitope of vIL-6 [9].
The CBM of the IL-6R binds to site I of IL-6, whereas the
NH2-terminal Ig-like domain is dispensable for biological ac-
tivity [10], but may have a role in post-translational process-
ing of the receptor [11]. The complete crystal structure of the
extracellular domains of the IL-6R was solved recently [12].
Similar to the gp130 CBM, the two ¢bronectin domains of the
IL-6R CBM are oriented perpendicularly. Surprisingly, the
crystal structure revealed dimer formation of two IL-6R mol-
ecules along the long-axis of the two ¢bronectin domains of
the CBM. The large surface area buried between the contact
sites suggested, that this dimer may also exist on the cell sur-
face. Here, we show that dimerization of the IL-6R indeed
occurs not only on the cell surface, but also in solution.
2. Materials and methods
2.1. Preparation of IL-6R mutants
The human IL-6R was tagged at the COOH-terminus either with a
protein-C tag (IL-6R-PC, amino acid sequence including the last ¢ve
COOH-terminal residues of the IL-6R: FFPR-SL-EDQVDPR-
LIDGK) or a Haemophilus in£uenza tag (IL-6R-HA, FFPR-SR-
YPYDVPDYA). Recombinant human IL-6 was prepared as reported
before [13]. For immunoprecipitation and Western blot analysis, the
murine monoclonal antibody (mAB) MT-18, which recognizes the Ig-
like domain of the IL-6R [10,14], the anti-PC-tag mAB HPC4, the
anti-HA-tag mAB 12CA5 (both obtained from Roche Molecular Bio-
chemicals, Mannheim, Germany) and the anti-HA-tag rabbit poly-
clonal antibody sc805 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were used. The anti-HA-tag mAB 12CA5 was used only for
immunoprecipitation, the anti-HA-tag antibody sc805 only for West-
ern blot.
2.2. Immunoprecipitation and Western blot analysis
COS-7 cells were grown in Dulbecco’s minimal essential medium
supplemented with fetal calf serum (10%), penicillin and streptomycin.
Cells were transfected with either IL-6R-PC or IL-6R-HA or both
using the expression vector p409 [15]. Cells were lysed in 50 mM
Tris, pH 7.5, 150 mM NaCl, and 3 mM sodium orthovanadate, con-
taining a cocktail of protease inhibitors (Boehringer Mannheim, Ger-
many), phenylmethylsulfonyl £uoride (1 mM) and 1% Brij-96. Insolu-
ble material was pelleted and the supernatants immunoprecipitated
with the anti-PC tag, anti-HA tag or the MT-18 antibody. The com-
plexes were isolated with protein A^Sepharose CL-4B (Pharmacia,
Uppsala, Sweden), subjected to SDS^PAGE and transferred to a poly-
vinylidene di£uoride membrane (Amersham Life Science, England).
The membranes were incubated with an appropriate primary antibody
before being labelled with a secondary antibody coupled to peroxi-
dase. Subsequently, the membranes were developed using the Amer-
sham ECL plus kit.
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3. Results
The receptor mutants used and the recognition site of the
antibodies applied are depicted in Fig. 1. To validate the
speci¢c recognition of the tags by the antibodies used, COS-
7 cells were transfected with IL-6R-PC, IL-6R-HA or both
and lysed. 5 Wl of the lysate of a 10 cm dish were subjected to
SDS^PAGE and blotted either with the anti-PC antibody
HPC4 or the anti-HA antibody sc805 (Fig. 2A). The anti-
PC antibody HPC4 only recognized the PC-tagged IL-6R mu-
tant, but not the HA-tagged one. Similarly, the sc805 recog-
nized only the HA-tagged IL-6R. A possible concentration
e¡ect of the tagged IL-6R mutants by immunoprecipitation
with the IL-6R antibody MT18 did not change this pattern
(Fig. 2B). In all experiments, the IL-6R appeared as a double
band, re£ecting di¡erential glycosylation of the IL-6R on the
secretory pathway [11,16].
To ascertain the possible existence of IL-6R dimers in the
cell membrane, COS-7 cells double transfected with IL-6R-PC
and IL-6R-HA were lysed, the lysates precipitated with the
anti-PC antibody HPC4, subjected to SDS^PAGE and blot-
ted with the anti-HA antibody sc805 (Fig. 3A). A clear band
was detectable after this procedure, re£ecting HA-tagged mol-
ecules coprecipitated with the anti-PC tag antibody. Similarly,
the PC-tagged IL-6R was coprecipitated when the lysates were
precipitated with the anti-HA tag antibody 12CA5. The bands
were, however, much weaker, since the anti-HA tag antibodies
did not immunoprecipitate well (Fig. 3A, right panel). The
weaker band strength was not due to unequal expression of
IL-6R-PC and IL-6R-HA in the double transfected COS-7
cells, since a Western blot on the lysates from the double
transfected cells with either the anti-PC or the anti-HA anti-
body demonstrated roughly equal levels of IL-6R-PC and IL-
6R-HA (Fig. 2A). Addition of IL-6 (50 ng/ml) to the cells
prior to lysis did not a¡ect coprecipitation of the alternatively
tagged IL-6R. Since the possibility remained that only a pro-
portion of the IL-6Rs at the cell surface had bound IL-6, we
increased the IL-6 concentration up to 1 Wg/ml. However,
dimer formation of the di¡erently tagged IL-6R mutants re-
mained una¡ected by IL-6 (Fig. 3B, lanes 3^6), the control
lanes (1 and 2) clearly showed that the signal in lanes 3^6
represented coprecipitated IL-6R. Although the signal seemed
to become stronger upon the addition of IL-6 (lanes 4 and 5),
in several other experiments (see Fig. 3A) we did not observe
any di¡erence in the coprecipitation in the absence and pres-
ence of IL-6. We next asked whether dimerization of the IL-
6R would also occur in solution. Therefore lysates from cells
only expressing IL-6R-PC or IL-6R-HA respectively were
mixed and subjected to either precipitation with the anti-PC
Fig. 1. Schematic representation of the IL-6R mutants prepared in-
cluding the recognition sites of the antibodies used for immunopre-
cipitation and Western blot.
Fig. 2. A: COS-7 cells transfected with IL-6R-PC, IL-6R-HA or both were lysed in 1 ml lysis bu¡er. 5 Wl of the lysate was subjected to SDS^
PAGE and blotted with the anti-PC antibody HPC4 (left panel) or with the anti-HA antibody sc805 (right panel) and as a loading control
with the anti-IL-6R antibody MT-18. B: COS-7 cells transfected with IL-6R-PC or IL-6R-HA were lysed and immunoprecipitated with the
anti-IL-6R antibody MT-18 before subjecting to SDS^PAGE. The receptors were detected with the anti-PC antibody HPC4 or with the anti-
HA antibody sc805 and as control with the anti-IL-6R antibody MT-18.
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or the anti-HA antibody. Coprecipitation of the alternatively
tagged IL-6R mutant was observed under both conditions
(Fig. 3C), con¢rming that dimerization of the IL-6R also
occurred in solution.
4. Discussion
An increasing body of evidence suggests that cytokine re-
ceptors in the plasma membrane are preassembled rather than
associated by ligand binding. This has been conclusively dem-
onstrated for the receptors for erythropoietin and growth hor-
mone [17^19] and more recently for the interferon-Q and IL-
10R [20,21]. Consequently, receptor dimerization per se is not
su⁄cient for receptor activation. Rather, ligand binding in-
duces changes in the spatial orientation of the receptor chains
that cause triggering of intracellular signalling cascades or
even inactivate receptor dimers [22,23]. However, in contrast
to the above mentioned receptors the K-receptors of the IL-6
family including the IL-6R are not involved in signal trans-
duction and have so far been presumed to exist as monomers.
The recent discovery of a large dimerization interface in the
crystal structure of the human IL-6R raised the possibility
that the IL-6R could dimerize in the two-dimensional surface
of the plasma membrane [12]. Our results clearly demonstrate
that this is indeed the case, but further illustrate that dimer-
ization of the IL-6R also occurs in solution. Furthermore,
IL-6 does not a¡ect IL-6R dimerization (Fig. 3B), although
IL-6 possesses only one binding epitope to the IL-6R (site I).
This excludes the possibility that IL-6R dimerization occurs
via the ligand binding epitope as in the erythropoietin recep-
tor dimer (Fig. 4A, [17]). Consequently, it appears very likely
that the IL-6R dimerization observed in our experiments oc-
curs via the dimerization interface observed in the crystal
structure [12]. Dimerization along the long axis of the do-
mains constituting the IL-6R CBM as suggested by Varghese
et al. would not prevent binding of IL-6 to the IL-6R in the
dimer (Fig. 4B). In line with this notion, published mutations
in the dimerization interface did not a¡ect ligand binding, but
slightly impaired signalling [12].
A somewhat speculative model for the hexameric IL-6R
complex was therefore suggested in which the two IL-6R mol-
ecules are still dimerized and which would therefore explain
the e¡ect of these mutations as a consequence of disturbed
dimerization [12]. The model is, however, di⁄cult to reconcile
Fig. 3. A: COS-7 cells double transfected with IL-6R-PC and IL-6R-HA were lysed in the absence or presence of IL-6 and subsequently immu-
noprecipitated with HPC4 and blotted with the anti-HA antibody sc805 (left panel) or precipitated with the anti-HA antibody 12CA5 and blot-
ted with the anti-PC antibody HPC4 (right panel). Loading was controlled by Western blot with the anti-IL-6R antibody MT-18 after strip-
ping. B: In lanes 1 and 2, COS-7 cells were single transfected with IL-6R-PC or IL-6R-HA, the lysates were immunoprecipitated with HPC4
and blotted with the anti-HA antibody sc805. The double transfected cells (lanes 3^6) were preincubated with increasing concentrations of IL-6
prior to lysis. C: Lysates (500 Wl) of single transfected COS-7 cells (IL-6R-PC or IL-6R-HA) were mixed, immunoprecipitated with HPC4 and
blotted with sc805 (left panel) or precipitated with the 12CA5 and blotted with the HPC4 antibody (right panel). Loading was controlled by
Western blot with the anti-IL-6R antibody MT-18 after stripping.
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with the geometry of the solved X-ray structure of the tetra-
meric vIL-6/gp130 complex which is considered an excellent
template for the hexameric IL-6R complex, since the epitopes
on vIL-6 that contact gp130 are identical to the gp130 binding
epitopes on IL-6 [9,24]. Taking into account a model for the
binding of IL-6 to the IL-6R [25], we and others have recently
derived a di¡erent model for the hexameric IL-6R complex
based on the vIL6/gp130 complex ([15,26], Fig. 4C). Here, the
interface of the IL-6R dimer (marked by an asterisk) faces
gp130 and mutations may well a¡ect signalling without any
e¡ect on ligand binding. Importantly, there is no space to
accommodate the second IL-6R molecule of the dimer which
implies that the IL-6R dimer dissolves upon formation of the
receptor complex. If one supposed that the dimer remained,
the IL-6R complex would be at least octameric and further-
more prone to form large aggregates via the IL-6R dimer.
Multimer or aggregate formation of the IL-6R alone is very
unlikely, since in contrast to the dimerization interface ob-
served in the crystal structure, all other epitopes of the IL-
6R (apart from the ligand binding epitope) are prone to gly-
cosylation, thus disabling them as potential dimerization sites.
Our results clearly show the existence of IL-6R dimers both
in the cell membrane and in solution. However, the function
of these dimers is unknown at present as and it is unclear how
the gp130 dimer in the active IL-6R complexes a¡ects the
preformed IL-6R dimer. Our ongoing work is concerned to
clarify these questions.
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Fig. 4. A: A possible IL-6R dimer based on the crystal structure of
the erythropoietin receptor would be disrupted by binding of IL-6.
B: Schematic representation of the IL-6R dimer observed in the
crystal structure. C: Model of the hexameric IL-6R complex derived
from the tetrameric vIL-6/gp130 complex (modi¢ed from [15,26]).
The asterisk denotes the dimer interface of the IL-6R in the crystal
structure. The IL-6R CBM is depicted in dark gray, the three NH2-
terminal domains of gp130 in light gray. The Ig-like domain of
gp130 contacts site III of IL-6, the CBM of gp130 site II as in the
vIL-6.
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